Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (15864)	6/19/2002 6:15:18 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Competition is not a problem at all, only Rebiff could create competition problems to Avonex, not any other company could be affected by competition, not xoma. UbsW put a strong buy on Dna, they claimed that xanelim will have a lot of competition, a smaller $1B market to share,$100Ms in 04, and immunesuppression perception problems, all that better than Amevive, the also put a buy on Icos and their IC747 (jumbo!)with their Lfa1 xanelim proof of concept also on the way, and medi507, is their view, not mine, send e-mail to kim guy, kim gal and the other guy who publihsed the report.